The pharmaceuticals and active pharmaceutical ingredients (APIs) supply chain is a critical supply chain that has been a particular focus of the Biden administration. The Biden administration has been pursuing policies aimed at increasing resilience in this supply chain by addressing shortages and minimising disruption through a range of measures, including efforts to on-shore and near-shore production to reduce reliance on foreign countries.

In this video, Kerry Contini, Maurice Bellan and Veleka Peeples-Dyer discuss some of the key legal and compliance considerations for companies operating in the pharmaceuticals and APIs supply chain, with a specific focus on the impacts of the Biden administration's policies on Food and Drug Administration regulations and government procurement.

Watch the video in full here.

For further information on this topic please contact Kerry Contini, Maurice Bellan or Veleka Peeples-Dyer at Baker McKenzie by telephone (+1 312 861 8000​) or email ([email protected], [email protected] or [email protected]). The Baker McKenzie website can be accessed at